尼莫地平联合茴拉西坦治疗血管性轻度认知障碍患者对认知功能的影响  

Effect of nimodipine combined with aniracetam on treatment of cognitive function in patients with vascular mild cognitive impairment

作　　者：殷琪[1] 许晋川[1] 吕静美[1] 黄奕君[1] 

机构地区：[1]海南省人民医院保健中心一区,海南海口570311

出　　处：《西部医学》2014年第12期1648-1649,1652,共3页Medical Journal of West China

摘　　要：目的探讨尼莫地平联合茴拉西坦治疗血管性轻度认知障碍患者对认知功能的影响。方法将102例血管性轻度认知障碍患者随机分为观察组和对照组各51例,对照组给予尼莫地平治疗,观察组给予尼莫地平联合茴拉西坦治疗,比较两组患者的临床疗效和认知功能变化情况。结果治疗3个月后观察组总有效率(92.16%)高于对照组(76.47%),组间差异有统计学意义(P<0.05);3个月后观察组MoCA和ADL评分[(18.69±2.47)分、(28.68±5.32)分]均优于对照组[(16.37±1.85)分、(32.46±7.05)分],差异均有统计学意义(均P<0.05)。结论尼莫地平联合茴拉西坦治疗血管性轻度认知障碍安全有效,提高了治疗效果,显著改善了患者认知功能,值得临床推广应用。Objective To investigate the effect of nimodipine combined with aniraeetam on treatment of cognition in patients with vascular mild cognitive impairment function. Methods 102 patients with vascular mild cognitive impairment were randomly divided into observation group and control group with 51 cases in each group. The control group was given nimodipine treatment. The observation group was given nimodipine combined with aniraeetam treatment. The clinical efficacy and cognitive function changes were compared in two groups. Results After three months, the total effective rate of observation group （92.16%） was higher than that of the control group （76.47%）. There was significant difference between the groups （P〈0.05）. After three months, the observation group MoCA and ADL score [（18.69 ± 2.47）, （28.68 ± 5.32）]. The points were superior to the control group [ （16.37± 1.85）, （32.46 ± 7.05）]. The differences were statistically significant（P〈0.05）. Conclusion Nimodipine combined with aniracetam is safe in the treatment of vascular mild cognitive impairment effectively.

关 键 词：血管性 轻度认知障碍 茴拉西坦 尼莫地平 认知功能 

分 类 号：R743[医药卫生—神经病学与精神病学]